{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:57:07Z","timestamp":1786636627243,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2012]]},"DOI":"10.4103\/0253-7613.91864","type":"journal-article","created":{"date-parts":[[2012,1,14]],"date-time":"2012-01-14T15:50:41Z","timestamp":1326556241000},"page":"36","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacokinetic approach for optimizing gentamicin use in neonates during the first week of life"],"prefix":"10.4103","volume":"44","author":[{"given":"AhmedS","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MFadulAllah","family":"Farouq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KhalidA","family":"Al-Faify","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.91864-1","unstructured":"Gomella TL, Cunningham MD, Eyal FG. Neonatology: Management, Procedures, On-Call Problems, Diseases, and Drugs. 5 th ed. New York: Lange Medical Books; 2004."},{"key":"key-10.4103\/0253-7613.91864-2","unstructured":"Levene MI, Tudehope DI, Thearle MJ. Essentials of Neonatal Medicine. 3 rd ed. Oxford: Blackwell Science; 2000."},{"key":"key-10.4103\/0253-7613.91864-3","first-page":"530","volume-title":"Observational trial of a 48-hour genatmicin dosing regimen derived from Monte Carlo simulations in infants born at less than 28 weeks\u2032 gestation","author":"Thingvoll","year":"2008","journal-title":"J Pediatr"},{"key":"key-10.4103\/0253-7613.91864-4","first-page":"163","volume-title":"Extended- interval dosing of genatmicin for treatment of neonatal sepsis in developed and developing countries","author":"Darmstadt","year":"2008","journal-title":"J Health Popul Nutr"},{"key":"key-10.4103\/0253-7613.91864-5","first-page":"71","volume-title":"Therapeutic drug monitoring of aminoglycosides in neonates","author":"Touw","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"key-10.4103\/0253-7613.91864-6","first-page":"39","volume-title":"Therapeutic drug monitoring of genatmicin in neonatal intensive care unit: Experience in 68 newborns","author":"Testa","year":"2007","journal-title":"J Chemother"},{"key":"key-10.4103\/0253-7613.91864-7","unstructured":"Zaske D, Shikoma L, Tholl D. Aminoglycosides. In: Taylor W, Diers CM, editors. A Textbook for Theclinical Application of Therapeutic Drug Monitoring. Irving: Abbott Laboratories; 1986. p. 285-320."},{"key":"key-10.4103\/0253-7613.91864-8","first-page":"522","volume-title":"A simple estimate of glomerular filtration rate in adolescent boys","author":"Schwartz","year":"1985","journal-title":"J Pediatr"},{"key":"key-10.4103\/0253-7613.91864-9","first-page":"F294","volume-title":"Aminoglycoside extended interval dosing in neonates is safe and effective: A meta-analysis","author":"Nestaas","year":"2005","journal-title":"Arch Dis Child"},{"key":"key-10.4103\/0253-7613.91864-10","first-page":"823","volume-title":"Prediction of gentamicin peak and trough concentrations from six extended-interval dosing protocols for neonates","author":"Murphy","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"key-10.4103\/0253-7613.91864-11","first-page":"473","volume-title":"High compared with standard genta dosing for chorioamnionitis: A comparison of maternal and fetal serum drug levels","author":"Locksmith","year":"2005","journal-title":"Obstet Gynecol"},{"key":"key-10.4103\/0253-7613.91864-12","first-page":"514","volume-title":"Population pharmacokinetics of genta in preterm neonates: Evaluation of a once-daily dosage regimen","author":"Vervelde","year":"1999","journal-title":"Ther Drug Monit"},{"key":"key-10.4103\/0253-7613.91864-13","first-page":"527","volume-title":"Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of genta in neonates","author":"Stolk","year":"2002","journal-title":"Ther Drug Monit"},{"key":"key-10.4103\/0253-7613.91864-14","unstructured":"Brunton LL, Lazo JS, Parker KL. The pharmacological basis of therapeutics. In: Goodman, Gilmans, editors. 11 th ed. New York: McGraw-Hill; 2006."},{"key":"key-10.4103\/0253-7613.91864-15","first-page":"25","volume-title":"Mechanistic basis of using body size and maturation to predict clearance in humans","author":"Anderson","year":"2009","journal-title":"Drug Metab Pharmacokinet"},{"key":"key-10.4103\/0253-7613.91864-16","first-page":"54","volume-title":"The effect of sepsis upon gentamicin pharmacokinetics in neonates","author":"Lingvall","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"key-10.4103\/0253-7613.91864-17","first-page":"1091","volume-title":"The kinetic profile of genta in premature neonates","author":"Rocha","year":"2000","journal-title":"J Pharm Pharmacol"},{"key":"key-10.4103\/0253-7613.91864-18","first-page":"92","volume-title":"Genta in preterm neonates: An extended interval dosing scuduale","author":"Veltkamp","year":"2007","journal-title":"Eur J Hosp Pharm Sci"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:59:11Z","timestamp":1786633151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0253-7613.91864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"alternative-id":["91864"],"URL":"https:\/\/doi.org\/10.4103\/0253-7613.91864","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2012]]}}}